Researchers Find Marker for Severity in Adult Brain Cancer

	Tweet

Researchers at UT Southwestern Medical Center have identified a new biological indicator that may help identify which brain-cancer patients have the most aggressive forms of the disease.

The researchers found that an inflammation-related molecule called RIP1 is commonly found in high levels in glioblastoma, the most common primary malignant brain tumor in adults. The protein RIP1 is a component of the complex NF-kB signaling network – a family of proteins that play a key role in inflammation-induced cancer.

The study, available online and published in the April issue of Cancer Research, could provide a new target for therapeutic drugs for glioblastoma patients who have a high level of RIP1 in their tumors coupled with NF-kB activation. 

“This is the first report of high RIP1 levels being associated with any type of cancer,” said Dr. Amyn Habib, assistant professor of neurology at UT Southwestern and the study’s senior author. “Our data suggests that increased expression of RIP1 could serve as a marker to identify patients who have a significantly worse prognosis and who will likely be resistant to chemotherapy.”

Glioblastoma multiforme (GBM), a cancer of the supportive tissue of the brain, is resistant to treatment. GBM can infiltrate the brain extensively and sometimes become large before turning symptomatic. The median survival of patients with GBM is about 15 months after diagnosis, even with radiation and chemotherapy treatments.

In the study, researchers examined tumor tissues from 92 patients to determine the distribution of RIP1 in each. They found that the most malignant form of the tumors, which also are the most common, had highest levels of RIP1.

One of the next steps is to determine whether these patients may respond better to drugs targeting the NF-kB network. There are many drugs currently available that target these proteins.

Another significant finding of the study is the protein RIP1 regulates the function of p53, a tumor suppressor gene that inhibits the growth of tumors.

“RIP1 activates NF-kB and then that increases the expression of a gene called mdm2, which inhibits the p53 gene,” Dr. Habib said. “Inhibition of p53 allows cells with damaged DNA to proliferate and potentially to become cancerous.”

Dr. Habib cautioned that the results are preliminary and more research is needed to investigate possible therapeutic strategies.

“We’ve found a correlation,” Dr. Habib said. “If RIP1 is increased, patients do worse; however, we don’t know whether this molecule has some causal role in pathogenesis.”

Other UT Southwestern researchers involved in the study were co-lead author Dr. Seongmi Park, postdoctoral fellow in radiation oncology; co-lead author Dr. Kimmo Hatanpaa, assistant professor of pathology; Dr. Yang Xie, assistant professor of clinical sciences; Dr. Bruce Mickey, professor of neurological surgery and of otolaryngology – head and neck surgery; Dr. Christopher Madden, assistant professor of neurological surgery; Dr. Jack Raisanen, associate professor of pathology; Dr. Guanghua Xiao, assistant professor of clinical sciences; Dr. Debabrata Saha, assistant professor of radiation oncology; Dr. David Boothman, professor of pharmacology and radiation oncology; Dr. Dawen Zhao, assistant professor of radiology; and Dr. Robert Bachoo, assistant professor of neurology. Drs. Boothman, Habib, Xie and Bachoo are also affiliated with the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern.

The research was partly funded by a grant from the Department of Energy.

Visit http://www.utsouthwestern.org/cancercenter to learn more about UT Southwestern’s clinical services in cancer at UT Southwestern. Visit http://www.utsouthwestern.org/neurosciences to learn more about UT Southwestern’s clinical services in the neurosciences, including neuro-oncology.

Source: UT Southwestern Medical Center

RELATED STORIES:
Factors behind head and neck cancer revealed   Gene expression to distinguish metastasizing from non-metastasizing head and neck cancers   Gene therapy increases survival for end-stage head and neck cancer   Munition exposure linked to brain cancer in US vets   First animal model that mimics human head and neck cancer   Cause and treatment for aggressive head and neck cancer may have been found   Study Finds Promising Chemoradiation Therapy   Early detection critical in treating pediatric thyroid cancer   Most common adult brain cancer linked to gene deletion, Stanford doctors say   New Surgery Improves Head & Neck Cancer Treatment   Disparities among patients with extremity soft-tissue sarcomas   New Protocol Targets Aggressive Brain Cancer   HK surgeons upbeat on brain cancer removal method   New treatment combination proves safe, effective for head and neck cancer patients   Robotic Surgery for Head and Neck Cancer Shows Promise   Researchers Identify Best Treatments for Long-Term Survival in Brain Tumor Patients   New Imaging Analysis Predicts Brain Tumor Survival   Psychiatric symptoms can be first sign of cancer   Signaling System Found that Halts the Growth of a Childhood Brain Cancer   Combining radiation therapy, chemotherapy safely treats head and neck cancer patients   Study finds no brain tumor link with mobile phones   Celldex brain cancer vaccine doubles survival

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]